NCT06152809 2026-03-18
CIML NK Cells With Venetoclax for AML
Dana-Farber Cancer Institute
Phase 1 Recruiting
Clinical Trials
418 trialsNCT05735184 2026-03-13
A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML
Kura Oncology, Inc.
Phase 1 Recruiting
NCT07464951 2026-03-11
CART123
Children's Hospital of Philadelphia
Phase 1 Not yet recruiting
NCT06021600 2026-03-09
A Phase 1, Open-Label, Sequential Cross-over, Bioavailability/Bioequivalence Study to Compare the Pharmacokinetics of Oral Cladribine With the Reference Listed Drug, Intravenous Cladribine
M.D. Anderson Cancer Center
Phase 1 Active not recruiting
NCT07044544 2026-03-04
Trial of Novel Anti-leukemia Agents in Flu/Mel RIC Transplant for Myeloid Malignancies
University of Alabama at Birmingham
Phase 1 Recruiting
NCT07439211 2026-03-03
GAVEL
Dana-Farber Cancer Institute
Phase 1 Not yet recruiting
NCT05170828 2026-02-24
Cryopreserved MMUD BM With PTCy for Hematologic Malignancies
Ossium Health, Inc.
Phase 1 Withdrawn
NCT06522373 2026-02-24
Phase I Trial of MT-0169 in CD38+ Acute Leukemia With Relapsed/Refractory or Measurable Residual Disease
M.D. Anderson Cancer Center
Phase 1 Withdrawn
NCT06408194 2026-02-10
Autologous CD22 CAR T Cells Following Commercial CD19 CAR T Cells in B Cell Malignancies
Stanford University
Phase 1 Recruiting
NCT06810583 2026-02-03
A Prospective Trial of Dalbavancin-Based Prophylaxis in Children and Adolescents With High-Risk Leukemia
St. Jude Children's Research Hospital
Phase 1 Recruiting
NCT05787496 2026-01-28
A Safety, Tolerability and Efficacy Study of NC525 in Subjects With Advanced Myeloid Neoplasms
NextCure, Inc.
Phase 1 Terminated
NCT03829540 2026-01-22
CD4CAR for CD4+ Leukemia and Lymphoma
Indiana University
Phase 1 Recruiting
NCT06768476 2026-01-16
AML
University of Pennsylvania
Phase 1 Active not recruiting
NCT05544968 2026-01-12
Anti-CD30 biAb-AATC in Patients With Relapsed/Refractory CD30 Positive Hematopoietic Malignancies
Medical College of Wisconsin
Phase 1 Not yet recruiting
NCT04874480 2026-01-09
Tegavivint for the Treatment of Relapsed or Refractory Leukemia
M.D. Anderson Cancer Center
Phase 1 Active not recruiting
NCT06649006 2026-01-08
Study to Investigate Intravenous Blinatumomab in Japanese Adult Participants With Newly Diagnosed Philadelphia-negative B-precursor Acute Lymphoblastic Leukemia (B-ALL)
Amgen
Phase 1 Completed
NCT02787369 2026-01-07
ACY-1215 in Combination With BCR Pathway Inhibitors in Relapsed CLL
Dana-Farber Cancer Institute
Phase 1 Active not recruiting
NCT03760523 2026-01-07
Dose Escalation Study of Minnelide in Relapsed or Refractory Acute Myeloid Leukemia
H. Lee Moffitt Cancer Center and Research Institute
Phase 1 Terminated
NCT04024761 2026-01-02
A Phase 1 Trial of CIML NK Cell Infusion for Myeloid Disease Relapse After Hematopoietic Cell Transplantation
Dana-Farber Cancer Institute
Phase 1 Recruiting
NCT06138587 2026-01-02
Preemptive CIML NK Cell Therapy After Hematopoietic Stem Cell Transplantation
Dana-Farber Cancer Institute
Phase 1 Recruiting
NCT07297173 2025-12-22
Phase 1 Study of Chemotherapy Plus HLA-mismatched GPBMC Infusion Bridging to Allo-HSCT for R/R Leukemia
Beijing 302 Hospital
Phase 1 Recruiting
NCT04077307 2025-12-19
MAATEO
Thomas Helleday Foundation
Phase 1 Recruiting
NCT03330691 2025-12-15
A Feasibility and Safety Study of Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy for CD19+CD22+ Leukemia
Seattle Children's Hospital
Phase 1 Active not recruiting
NCT04629729 2025-12-11
FT819 in Subjects With B-cell Malignancies
Fate Therapeutics
Phase 1 Active not recruiting
NCT06001788 2025-12-03
Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia
Kura Oncology, Inc.
Phase 1 Recruiting
NCT02381886 2025-11-10
A Study of IDH305 in Patients With Advanced Malignancies That Harbor IDH1R132 Mutations
Novartis
Phase 1 Active not recruiting
NCT02996773 2025-11-10
Haploidentical BMT With Post-Transplant Cyclophosphamide and Bendamustine
University of Arizona
Phase 1 Completed
NCT06549790 2025-10-31
Study of NMS-03597812 in Adult Patients With Relapsed/Refractory Acute Myeloid Leukemia
Nerviano Medical Sciences
Phase 1 Recruiting
NCT03263936 2025-10-16
Epigenetic Reprogramming in Relapse/Refractory AML
Therapeutic Advances in Childhood Leukemia Consortium
Phase 1 Completed
NCT02512926 2025-10-15
POE14-01
Stanford University
Phase 1 Completed
NCT04678336 2025-10-15
CD123 Redirected T Cells for AML in Pediatric Subjects
University of Pennsylvania
Phase 1 Terminated
NCT05470140 2025-09-30
A Phase 1 Study of WU-NK-101 in Patients With Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML)
Wugen, Inc.
Phase 1 Completed
NCT03770429 2025-09-29
AZD6738 for Patients With Progressive MDS or CMML
Massachusetts General Hospital
Phase 1 Active not recruiting
NCT05168202 2025-09-25
A Study to Assess the Effect of CC-95251 in Participants With Acute Myeloid Leukemia and Myelodysplastic Syndromes
Bristol-Myers Squibb
Phase 1 Terminated
NCT06501196 2025-09-24
A Study of BH-30236 in Relapsed/ Refractory Acute Myelogenous Leukemia and Higher Risk Myelodysplastic Syndrome
BlossomHill Therapeutics
Phase 1 Recruiting
NCT02935257 2025-09-23
ALLCAR19
University College, London
Phase 1 Active not recruiting
NCT05993949 2025-09-23
Study of Brexucabtagene Autoleucel Plus Dasatinib in Adults With Acute Lymphoblastic Leukemia
Stanford University
Phase 1 Active not recruiting
NCT05823571 2025-09-18
Itacitinib With High-dose Posttransplantation Cyclophosphamide in Older Patients
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 1 Active not recruiting
NCT05983965 2025-09-10
Study of Tazemetostat in Lymphoid Malignancies
University of Alabama at Birmingham
Phase 1 Recruiting
NCT07120607 2025-08-13
Allogeneic CD7 CAR γδ T Cells Therapy Recurrent/Refractory Leukemia
Anhui Provincial Hospital
Phase 1 Not yet recruiting
NCT06340737 2025-08-07
AutologousCD22 Chimeric Antigen Receptor (CAR)T Cells in w/Recurrent/Refractory B Cell Lymphomas
Stanford University
Phase 1 Recruiting
NCT03766126 2025-06-26
Lentivirally Redirected CD123 Autologous T Cells in AML
University of Pennsylvania
Phase 1 Active not recruiting
NCT03186118 2025-06-17
Pilot Study of T-APCs Following CAR T Cell Immunotherapy for CD19+ Leukemia
Seattle Children's Hospital
Phase 1 Active not recruiting
NCT03244306 2025-06-17
PLAT-04
Seattle Children's Hospital
Phase 1 Active not recruiting
NCT02848001 2025-06-12
A Dose-finding Study of CC-90009 in Subjects With Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or Refractory Higher-risk Myelodysplastic Syndromes
Celgene
Phase 1 Terminated
NCT05248685 2025-06-11
Optimized Dual CD33/CLL1 CAR T Cells in Subjects With Refractory or Relapsed Acute Myeloid Leukemia
Beijing Boren Hospital
Phase 1 Withdrawn
NCT05290155 2025-06-06
Anti-CD7 CAR-T Cell Therapy for Relapse and Refractory CD7 Positive T Cell Malignancies
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Phase 1 Completed
NCT02975687 2025-06-03
CD19 CAR T Cells in Patients With Resistant or Refractory CD19+ Acute Lymphoblastic Leukemia
Institute of Hematology & Blood Diseases Hospital, China
Phase 1 Completed
NCT01044069 2025-05-23
Precursor B Cell Acute Lymphoblastic Leukemia (B-ALL) Treated With Autologous T Cells Genetically Targeted to the B Cell Specific Antigen CD19
Memorial Sloan Kettering Cancer Center
Phase 1 Active not recruiting
NCT03219450 2025-05-22
A Personalized Neoantigen Cancer Vaccine in Treatment Naïve, Asymptomatic Patients With IGHV Unmutated CLL.
Dana-Farber Cancer Institute
Phase 1 Recruiting